Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Equity (2020 - 2025)

C4 Therapeutics' Return on Equity history spans 6 years, with the latest figure at 0.51% for Q4 2025.

  • For Q4 2025, Return on Equity fell 5.0% year-over-year to 0.51%; the TTM value through Dec 2025 reached 0.51%, down 5.0%, while the annual FY2025 figure was 0.44%, 1.0% up from the prior year.
  • Return on Equity reached 0.51% in Q4 2025 per CCCC's latest filing, up from 0.73% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.21% in Q4 2021 to a low of 0.73% in Q3 2025.
  • Average Return on Equity over 5 years is 0.43%, with a median of 0.45% recorded in 2024.
  • The largest YoY upside for Return on Equity was 85bps in 2021 against a maximum downside of -60bps in 2021.
  • A 5-year view of Return on Equity shows it stood at 0.21% in 2021, then tumbled by -97bps to 0.42% in 2022, then tumbled by -36bps to 0.57% in 2023, then increased by 20bps to 0.46% in 2024, then fell by -11bps to 0.51% in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Return on Equity are 0.51% (Q4 2025), 0.73% (Q3 2025), and 0.6% (Q2 2025).